Compare GLP & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLP | XERS |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2005 | 2021 |
| Metric | GLP | XERS |
|---|---|---|
| Price | $52.59 | $8.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $46.00 | $10.83 |
| AVG Volume (30 Days) | 65.4K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.40% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,561,421,000.00 | $49,590,000.00 |
| Revenue This Year | $64.13 | $34.37 |
| Revenue Next Year | $11.74 | $22.86 |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | 8.14 | ★ 142.67 |
| 52 Week Low | $39.58 | $5.25 |
| 52 Week High | $53.00 | $10.08 |
| Indicator | GLP | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 53.11 |
| Support Level | $46.01 | $8.00 |
| Resistance Level | N/A | $9.01 |
| Average True Range (ATR) | 0.92 | 0.30 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 94.67 | 37.01 |
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.